Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Sarepta therapeutics, inc. save search
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Published: 2024-01-16 (Crawled : 23:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -1.19%
H: 1.04%
C: -0.02%
srp-9003 treatment therapeutics study
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $15.925 -1.15% 120K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD | $1.42 7.58% 100K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
Published: 2023-06-22 (Crawled : 18:00) - fda.gov
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -3.2%
H: 0.03%
C: -4.89%
fda treatment duchenne therapy
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
Published: 2022-09-29 (Crawled : 14:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: 0.03%
H: 1.51%
C: -0.28%
srp-9001 treatment application license therapeutics duchenne
Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -0.38%
H: 0.55%
C: -0.26%
srp-5051 treatment fda lifted therapeutics duchenne clinical hold
Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Published: 2021-08-30 (Crawled : 08:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -0.24%
H: 0.97%
C: -2.94%
treatment gene therapy therapy gene therapies
Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy for the Treatment of GM1 Gangliosidosis
Published: 2021-07-08 (Crawled : 20:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -0.43%
H: 2.2%
C: 1.76%
treatment fda fda fast track fast track gene therapy therapy gene therapies fast track designation designation
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Published: 2021-06-11 (Crawled : 08:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -0.86%
H: 0.91%
C: 0.0%
treatment gene therapy therapy license gene therapies syndros
Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Published: 2021-06-09 (Crawled : 18:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -0.24%
H: 5.87%
C: 4.1%
treatment gene therapy therapy gene therapies
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001
Published: 2021-05-18 (Crawled : 17:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: 5.51%
H: 7.83%
C: 2.74%
treatment gene therapy therapy duchenne gene therapies
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
Published: 2021-05-18 (Crawled : 13:00) - globenewswire.com
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: 5.51%
H: 7.83%
C: 2.74%
treatment gene therapy therapy duchenne gene therapies commercialization
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Published: 2021-04-30 (Crawled : 22:00) - biospace.com/
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: -0.43%
H: 1.54%
C: -0.37%
treatment duchenne
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
Published: 2021-03-18 (Crawled : 21:00) - globenewswire.com
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: 3.51%
H: 0.05%
C: -3.81%
treatment gene therapy therapy gene therapies
FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation
Published: 2021-02-25 (Crawled : 16:36) - fda.gov
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: 0.73%
H: 2.11%
C: 1.39%
fda treatment duchenne approval fda approval rare
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
Published: 2021-02-25 (Crawled : 20:25) - globenewswire.com
SRPT | $115.845 -0.61% 120K
|
Health Technology
|
| O: 0.73%
H: 2.11%
C: 1.39%
treatment fda fda approval injection approval duchenne dmd
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Published: 2020-12-04 (Crawled : 21:06) - globenewswire.com
SRPT | $115.845 -0.61% 120K
|
Health Technology
| Email alert
Add to watchlist
treatment duchenne
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.